A landmark ruling in Arizona has overturned previous decisions, declaring that driving after consuming marijuana is not punishable if the driver is not impaired. This decision highlights the growing recognition that THC detection alone does not necessarily indicate impairment and emphasizes the need for stricter regulations based on actual impairment.
Ohio’s recreational marijuana market is thriving, with sales reaching $76.3 million since August. However, despite strong initial sales, Michigan’s established market continues to dominate, with sales exceeding $295.4 million in August. This disparity is attributed to lower prices in Michigan, driving Ohio residents across the border for their cannabis needs. While Ohio’s industry shows promise, competition will likely intensify as more licenses are issued for growers and processors, potentially leading to more competitive pricing.
Leading Democrats in the House are calling on the DEA to swiftly reschedule cannabis from Schedule I to Schedule III, following recommendations from the Biden administration. They argue that cannabis has a lower abuse potential than other drugs and is medically beneficial. The lawmakers also urge further reform, including potential descheduling, aligning cannabis policy with scientific advancements.
Cannabis sales are booming in North Carolina’s first recreational marijuana dispensary, Great Smoky, located on the Qualla Boundary of the Eastern Band of Cherokee Indians. Meanwhile, multiple new cannabis dispensaries have opened in Florida, New York, Vermont, Illinois, Pennsylvania, Louisiana, and California, highlighting the growing legalization and accessibility of cannabis across the United States.
Thailand’s new cannabis bill aims to regulate the booming marijuana industry, shifting focus towards medical and health-related uses. This move follows the country’s 2022 decriminalization, making it the first in Asia to take such action. The bill proposes stricter regulations for growers, sellers, and related businesses while also allowing for medicinal and research uses, with penalties for recreational use.
The potential reclassification of marijuana from a Schedule I to a Schedule III drug could significantly impact the pre-roll industry. This article explores the potential benefits of reclassification, including reduced tax burdens, increased access to banking, and opportunities for research and development. It also highlights the importance of preparing for increased competition and strategizing for future success.
A new poll reveals a significant shift in Texan attitudes towards marijuana, with a majority favoring decriminalization. The poll, conducted by the University of Texas/Texas Politics Project, found that 68% of Texans, including a majority of Republicans, support reducing penalties for cannabis possession or use to a citation and fine. This trend mirrors a growing movement across the state, with several cities adopting decriminalization policies and activists pushing for ballot measures.
This week brings exciting developments in the cannabis industry, including the opening of North Carolina’s first legal recreational cannabis store, challenges faced by D.C. medical dispensaries, and Trulieve’s expansion across the nation. Read on for the latest news and insights.
Former President Donald Trump’s recent support for cannabis legalization in Florida has sent ripples through the cannabis market, causing a mixed reaction among cannabis stocks. While some companies saw gains, reflecting optimism about potential federal changes, others experienced significant drops. This comes as Florida prepares for a November vote on a recreational cannabis initiative, which could significantly impact the industry.
The Biden administration’s attempt to reschedule marijuana from a Schedule I drug is driven by politics, not science. Despite the DEA’s objections and the lack of scientific evidence supporting its medical use, the administration is pushing forward, ignoring the risks of addiction, mental health issues, and the potential for increased drug abuse. This move is not only a threat to public health but also a dangerous precedent for prioritizing political gain over scientific evidence and the rule of law.
